SITUATION/CHALLENGE
The sponsor initially recruited Viracor Eurofins for rapid transfer of an ELISpot assay, before recognizing the value and efficiency of being able to rely on the broad technical expertise of Viracor as a single provider for all assay optimization, validation and transfer requirements of the trial. Consequently, the success of the first project was soon followed by an expanded request for combined development and transfer for a Neutralizing Antibody (NAb) assay. Ultimately, Viracor was asked to develop, validate and perform multiple biomarker assays including ELISpot and NAb, with a qPCR assay added later as an endpoint.
No articles were found.